Dr. Stefano Cereda

Specialised Oncologist

Pancreatic Cancer – Gallbladder Cancer – Bile Duct Cancer – Long Standing experience in gastric and esophageal cancer

“The reason for the art of Medicine is health, the goal is to obtain it.”
– Galeno –

“To know the natural progress of an illness is to know more than half the knowledge on medicine”
– Armand Trousseau –

“The power of words on the soul is similar to the power of pharmaceutical drugs on the body.”
– Gorgia da Leontini –

IRCCS San Raffaele Hospital in Milano (since 2005)

– 1st Level Medical Director in the Division of Oncology at the San Raffaele Hospital in Milan

Research and Clinical activity

Dr. Stefano Cereda is specialised in the treatment of neoplastic diseases of the gastrointestinal tract (pancreatic cancergall bladder cancerbile duct tumors, stomach and esophagus cancer). He performs clinical research activities focused on pancreatic cancer and bile duct tumours, such as gallbladder tumours, Vater papilla, intra-hepatic and extra-hepatic biliary tract cancer. Winner in 2010 of the Grant instituted by ROL network and funded by the Lombardary Region for: “a Phase ii randomized second-line chemotherapy study with capecitabine versus capecitabine plus mitmycin in the treatment of advanced biliary adenocarcinoma”.

Awards and recognitions

2010 – Winner of the Fondazione Federico Calabresi Award for the best publication realised by a young oncologist (under 40).

Other Activities

Spokesman for 3 national congresses (Italian Association of Medical Oncology and AIOM YOUNG in 2008, 2010 and 2013)

In 2012 member of the scientific committee NSM Group for the organization of ECM formation courses.

In 2015 founder of the GICO Italian Group Colangiocarcinoma.

In 2017 reviewer of the texts on gastrointestinal tumours of Ultraspecialisti.com website.

Education and Training

Degree in Medicine and Surgery at the State University of Milan (2000)

Specialisation in Medical Oncology at the National Cancer Institute of Milan (2000-2004)

Registered to the Certified Medical Association

State examination and registration at the provincial order of doctors and surgeons of Milan, Albo dei Medici, n° 37395.

Medical Career and Medical Memberships

Since 2005 Medical Oncologist at the IRCCS San Raffaele Hospital in Milan

From 2000 to 2004 specialised Oncologist at the National Tumours Institute IRCCS in Milan

– Member of AIOM Italian Association for Medical Oncology

– Member of ASCO American Society of Clinical Oncology

– Member of ESMO European Society for Medical Oncology

Languages

Italian – English

Treated cancer diseases

Pancreatic Cancer
Gallbladder Cancer
Bile Duct Cancer
Long Standing experience in gastric and esophageal cancer

San Raffaele Hospital
Division of Oncology
Via Olgettina 60
20132 Milan, Italy


Contact

Per prenotare una visita ambulatoriale in libera professione: 02 26432020

Per prenotare una visita ambulatoriale tramite SSN: 02 26432643


Online medical consultation with Dr. Stefano Cereda

Operated pancreatic cancer: new therapeutic standard

Operated pancreatic cancer: new therapeutic standard

Operated pancreatic cancer: New therapeutic standard Article by Dr. Stefano CeredaOncologist specialized in Pancreatic cancerSan Raffaele Hospital in Milan, Italy…

Leggi tutto l'articolo
Telemedicine. The 4.0 version of Doctor-Patient interaction

Telemedicine. The 4.0 version of Doctor-Patient interaction

Telemedicine. The 4.0 version of Doctor-Patient interaction. Article by Stefano CeredaSpecialized OncologistSan Raffaele Hospital in Milano Clinical Telemedicine is an…

Leggi tutto l'articolo

Co-author of over 50 publications on principal international scientific journals and 10 publications as first author.

First author and co-author of over 100 communications in national and international conferences.

I suoi lavori/articoli sono pubblicati sulle principali riviste scientifiche internazionali, quali: Cancer, Annals of Oncology, Cancer Chemotherapy and Pharmacology, British Journal of Cancer, European Journal of Cancer.

Reviewer of scientific papers of some important medical journals: Annals of Oncology, Cancer Chemotherapy and Pharmacology, Tumori journal, Pancreas Journal, World Journal of Gastroenterology, Current Medical Research & Opinion, Cellular Physiology and Biochemistry, Gastroenterology Research and Practice, BMC Cancer, Expert Review of Anticancer Therapy, British Journal of Cancer, BioMed Research International, Frontiers in Oncology.

Publications

Bone metastases in biliary cancers: A multicenter retrospective survey.
Santini D, Brandi G, Aprile G, Russano M, Cereda S, Leone F, Lonardi S, Fornaro L, Scartozzi M, Silvestris N, Barni S, Pantano F, Vincenzi B, Palloni A, Frega G, Casagrande M, Ferrari L, Dadduzio V, Intini R, Filippi R, Vasile E, Vivaldi C, Faloppi L, Brunetti O, Reni M, Aglietta M, Tonini G.
J Bone Oncol. 2018 Apr 7;12:33-37. doi: 10.1016/j.jbo.2017.11.006. eCollection 2018 Sep.

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.
Peraldo-Neia C, Cavalloni G, Fenocchio E, Cagnazzo C, Gammaitoni L, Cereda S, Nasti G, Satolli MA, Aprile G, Reni M, Avallone A, Spadi R, Venesio T, Martin V, Doglioni C, Frattini M, Aglietta M, Leone F.
PLoS One. 2018 Jan 19;13(1):e0191593. doi: 10.1371/journal.pone.0191593. eCollection 2018.

Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study.
Venturini M, Sallemi C, Agostini G, Marra P, Cereda S, Reni M, Aldrighetti L, De Cobelli F, Del Maschio A.
Br J Radiol. 2016 Nov;89(1067):20160247.

Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.
Fornaro L, Vivaldi C, Cereda S, Leone F, Aprile G, Lonardi S, Silvestris N, Santini D, Milella M, Caparello C, Musettini G, Pasquini G, Falcone A, Brandi G, Sperduti I, Vasile E; GICO group (Gruppo Italiano COlangiocarcinoma).
J Exp Clin Cancer Res. 2015 Dec 23;34:156. doi: 10.1186/s13046-015-0267-x.

Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.
Cereda S, Milella M, Cordio S, Leone F, Aprile G, Galiano A, Mosconi S, Vasile E, Santini D, Belli C, Auriemma A, Novarino A, Vaccaro V, Martines C, Marino D, Lutrino SE, Palazzo V, Reinach B, Aldrighetti L, Reni M.
Cancer Chemother Pharmacol. 2016 Jan;77(1):109-14. doi: 10.1007/s00280-015-2919-0.

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M.
Cancer. 2016 Feb 15;122(4):574-81. doi: 10.1002/cncr.29778.

(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.
Reni M, Dugnani E, Cereda S, Belli C, Balzano G, Nicoletti R, Liberati D, Pasquale V, Scavini M, Maggiora P, Sordi V, Lampasona V, Ceraulo D, Di Terlizzi G, Doglioni C, Falconi M, Piemonti L.
Clin Cancer Res. 2016 Mar 1;22(5):1076-85. doi: 10.1158/1078-0432.CCR-15-1722.

Second-line chemotherapy in advanced biliary cancer: the present now will later be past.
Vivaldi C, Fornaro L, Cereda S, Aprile G, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Brandi G, Vasile E.
Ann Oncol. 2014 Dec;25(12):2443-4. doi: 10.1093/annonc/mdu379. Epub 2014 Aug 13.

In reply to Ren et al.
Passoni P, Reni M, Cattaneo GM, Slim N, Cereda S.
Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):431-2. doi: 10.1016/j.ijrobp.2014.02.003.

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.
Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Vivaldi C, Belli C, Bergamo F, Lutrino SE, Filippi R, Russano M, Vaccaro V, Brunetti AE, Rotella V, Falcone A, Barbera MA, Corbelli J, Fasola G, Aglietta M, Zagonel V, Reni M, Vasile E, Brandi G.
Br J Cancer. 2014 Apr 29;110(9):2165-9. doi: 10.1038/bjc.2014.190.

Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
Passoni P, Reni M, Cattaneo GM, Slim N, Cereda S, Balzano G, Castoldi R, Longobardi B, Bettinardi V, Gianolli L, Gusmini S, Staudacher C, Calandrino R, Di Muzio N.
Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1000-6. doi: 10.1016/j.ijrobp.2013.09.012.

Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial.
Reni M, Cereda S, Milella M, Novarino A, Passardi A, Mambrini A, Di Lucca G, Aprile G, Belli C, Danova M, Bergamo F, Franceschi E, Fugazza C, Ceraulo D, Villa E.
Eur J Cancer. 2013 Nov;49(17):3609-15. doi: 10.1016/j.ejca.2013.06.041.

Second-line therapy in advanced biliary tract cancer: what should be the standard?
Cereda S, Belli C, Rognone A, Mazza E, Reni M.
Crit Rev Oncol Hematol. 2013 Nov;88(2):368-74. doi: 10.1016/j.critrevonc.2013.05.010.

Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma.
Cattaneo GM, Passoni P, Longobardi B, Slim N, Reni M, Cereda S, di Muzio N, Calandrino R.
Radiother Oncol. 2013 Jul;108(1):66-71. doi: 10.1016/j.radonc.2013.05.011.

Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back.
Avan A, Pacetti P, Reni M, Milella M, Vasile E, Mambrini A, Vaccaro V, Caponi S, Cereda S, Peters GJ, Cantore M, Giovannetti E.
Int J Cancer. 2013 Aug 15;133(4):1016-22. doi: 10.1002/ijc.28078.

Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy.
Pecorelli N, Braga M, Doglioni C, Balzano G, Reni M, Cereda S, Albarello L, Castoldi R, Capretti G, Di Carlo V.
J Gastrointest Surg. 2013 Mar;17(3):488-93. doi: 10.1007/s11605-012-2063-7.

Neoadjuvant therapy in resectable pancreatic cancer: a critical review.
Belli C, Cereda S, Anand S, Reni M.
Cancer Treat Rev. 2013 Aug;39(5):518-24. doi: 10.1016/j.ctrv.2012.09.008.

Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer.
Arcidiacono PG, Carrara S, Reni M, Petrone MC, Cappio S, Balzano G, Boemo C, Cereda S, Nicoletti R, Enderle MD, Neugebauer A, von Renteln D, Eickhoff A, Testoni PA.
Gastrointest Endosc. 2012 Dec;76(6):1142-51. doi: 10.1016/j.gie.2012.08.006.

Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma.
Aprile G, Avellini C, Reni M, Mazzer M, Foltran L, Rossi D, Cereda S, Iaiza E, Fasola G, Piga A.
Tumour Biol. 2013 Feb;34(1):131-7. doi: 10.1007/s13277-012-0520-2.

Role of taxanes in pancreatic cancer.
Belli C, Cereda S, Reni M.
World J Gastroenterol. 2012 Sep 7;18(33):4457-65. doi: 10.3748/wjg.v18.i33.4457.

Adjuvant treatment in biliary tract cancer: to treat or not to treat?
Cereda S, Belli C, Reni M.
World J Gastroenterol. 2012 Jun 7;18(21):2591-6. doi: 10.3748/wjg.v18.i21.2591.

Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Reni M, Balzano G, Aprile G, Cereda S, Passoni P, Zerbi A, Tronconi MC, Milandri C, Saletti P, Rognone A, Fugazza C, Magli A, Di Muzio N, Di Carlo V, Villa E.
Ann Surg Oncol. 2012 Jul;19(7):2256-63. doi: 10.1245/s10434-011-2205-2.

Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.
Giovannetti E, Pacetti P, Reni M, Leon LG, Mambrini A, Vasile E, Ghidini M, Funel N, Lucchesi M, Cereda S, Peters GJ, Cantore M.
Pharmacogenomics. 2011 Dec;12(12):1641-52. doi: 10.2217/pgs.11.109.

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Reni M, Cereda S, Rognone A, Belli C, Ghidini M, Longoni S, Fugazza C, Rezzonico S, Passoni P, Slim N, Balzano G, Nicoletti R, Cappio S, Doglioni C, Villa E.
Cancer Chemother Pharmacol. 2012 Jan;69(1):115-23. doi: 10.1007/s00280-011-1680-2.

Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.
Cereda S, Reni M, Rognone A, Fugazza C, Ghidini M, Ceraulo D, Brioschi M, Nicoletti R, Villa E.
Chemotherapy. 2011;57(2):156-61. doi: 10.1159/000324865.

Unity is strength: one, two, or more drugs against advanced pancreatic cancer?
Reni M, Cereda S, Belli C, Villa E.
Ann Oncol. 2011 Apr;22(4):987. doi: 10.1093/annonc/mdr008.

XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Cereda S, Reni M, Rognone A, Ghidini M, Belli C, Longoni S, Fugazza C, Brioschi M, Nicoletti R, Balzano G, Passoni P, Villa E.
Anticancer Res. 2010 Nov;30(11):4785-90.

Treatment trends in metastatic pancreatic cancer patients: Is it time to change?
Reni M, Pasetto LM, Passardi A, Milella M, Mambrini A, Cereda S, Aprile G, Tronconi MC, Berardi R, Cordio S, Sartori N, Rognone A, Pederzoli P, Falconi M.
Dig Liver Dis. 2011 Mar;43(3):225-30. doi: 10.1016/j.dld.2010.09.010.

A first principles based polarizable O(N) interatomic force field for bulk silica.
Kermode JR, Cereda S, Tangney P, De Vita A.
J Chem Phys. 2010 Sep 7;133(9):094102. doi: 10.1063/1.3475565.

The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
Cereda S, Passoni P, Reni M, Viganò MG, Aldrighetti L, Nicoletti R, Villa E.
Cancer. 2010 May 1;116(9):2208-14. doi: 10.1002/cncr.24970.

An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?
Reni M, Sartori N, Mambrini A, Berardi R, Passardi A, Milella M, Cereda S, Tronconi MC, Aprile G, Cordio S, Pasetto LM, Rognone A, Pederzoli P, Falconi M.
Anticancer Drugs. 2010 Apr;21(4):459-64. doi: 10.1097/CAD.0b013e328336f50e.

Weekly epirubicin as salvage therapy in patients with gemcitabine-resistant advanced pancreatic cancer.
Cereda S, Rognone A, Mazza E, Fugazza C, Ceraulo D, Villa E, Reni M.
J Chemother. 2009 Dec;21(6):698-700.

Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Zerbi A, Nicoletti R, Mazza E, Arcidiacono PG, Di Carlo V, Villa E.
Cancer Chemother Pharmacol. 2009 Nov;64(6):1253-9. doi: 10.1007/s00280-009-0995-8.

Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma.
Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Fugazza C, Mazza E, Zerbi A, Di Carlo V, Villa E.
Cancer. 2009 Jun 15;115(12):2630-9. doi: 10.1002/cncr.24302.

Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer.
Cereda S, Reni M.
J Chemother. 2008 Aug;20(4):509-12.

PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V.
Am J Clin Oncol. 2008 Apr;31(2):145-50. doi: 10.1097/COC.0b013e31814688f7.

Thermal-hydrogen promoted selective desorption and enhanced mobility of adsorbed radicals in silicon film growth.
Cereda S, Zipoli F, Bernasconi M, Miglio L, Montalenti F.
Phys Rev Lett. 2008 Feb 1;100(4):046105.

A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma.
Reni M, Berardi R, Mambrini A, Pasetto L, Cereda S, Ferrari VD, Cascinu S, Cantore M, Mazza E, Grisanti S.
Cancer Chemother Pharmacol. 2008 Sep;62(4):673-8. doi: 10.1007/s00280-007-0653-y.

Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study.
Reni M, Cereda S, Bonetto E, Viganò MG, Passoni P, Zerbi A, Balzano G, Nicoletti R, Staudacher C, Di Carlo V.
Cancer Invest. 2007;25(7):594-8.

Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients.
Mandalà M, Reni M, Cascinu S, Barni S, Floriani I, Cereda S, Berardi R, Mosconi S, Torri V, Labianca R.
Ann Oncol. 2007 Oct;18(10):1660-5.

PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
Reni M, Cereda S, Galli L.
Cancer Lett. 2007 Oct 18;256(1):25-8.

New therapies for pancreatic cancer: current standard.
Reni M, Cereda S.
JOP. 2007 Jan 9;8(1 Suppl):98-101.

Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial.
Reni M, Bonetto E, Cordio S, Passoni P, Milandri C, Cereda S, Spreafico A, Galli L, Bordonaro R, Staudacher C, Di Carlo V, Johnson CD.
Pancreatology. 2006;6(5):454-63.

Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
Reni M, Cereda S, Bonetto E, Viganò MG, Passoni P, Zerbi A, Balzano G, Nicoletti R, Staudacher C, Di Carlo V.
Cancer Chemother Pharmacol. 2007 Feb;59(3):361-7. Epub 2006 Jun 29.

Celiac disease and childhood cancer.
Cereda S, Cefalo G, Spreafico F, Catania S, Meazza C, Podda M, Terenziani M.
J Pediatr Hematol Oncol. 2006 Jun;28(6):346-9.

Rhabdomyosarcoma of the head and neck region: experience at the pediatric unit of the Istituto Nazionale Tumori, Milan.
Meazza C, Ferrari A, Casanova M, Massimino M, Luksch R, Spreafico F, Cefalo G, Terenziani M, Polastri D, Podda M, Catania S, Cereda S, Gandola L, Fossati-Bellani F, Cantù G.
J Otolaryngol. 2006 Feb;35(1):53-9.

Adult Wilms’ tumor: A monoinstitutional experience and a review of the literature.
Terenziani M, Spreafico F, Collini P, Piva L, Perotti D, Podda M, Gandola L, Massimino M, Cereda S, Cefalo G, Luksch R, Casanova M, Ferrari A, Polastri D, Valagussa P, Fossati-Bellani F.
Cancer. 2004 Jul 15;101(2):289-93.

Becker muscular dystrophy in a patient with Hodgkin’s disease.
Cereda S, Cefalo G, Terenziani M, Catania S, Fossati-Bellani F.
J Pediatr Hematol Oncol. 2004 Jan;26(1):72-3.

Amelanotic melanoma in a child with oculocutaneous albinism.
Terenziani M, Spreafico F, Serra A, Podda M, Cereda S, Belli F.
Med Pediatr Oncol. 2003 Aug;41(2):179-80.

How to apply for an online medical consultation

Register your details in the secure area and choose the doctor according to your disease.

Fill in the medical history form and upload your reports and clinical exams.

Enter your billing information and make the payment.

Within 5 working days you will receive the doctor’s online consultation.